Literature DB >> 34520593

MR spectroscopy and diffusion imaging in people with human immunodeficiency virus: Relationships to clinical and immunologic findings.

Susan Morgello1,2, Korhan Buyukturkoglu3, Jacinta Murray1, Mike Veenstra4, Joan W Berman4, Desiree Byrd1,5, Matilde Inglese6.   

Abstract

BACKGROUND AND
PURPOSE: People with human immunodeficiency virus (HIV; PWH) present a complex array of immunologic and medical disorders that impact brain structure and metabolism, complicating the interpretation of neuroimaging. This pilot study of well-characterized multi-morbid PWH examined how medical and immunologic factors predicted brain characteristics on proton MR spectroscopy (1H-MRS) and diffusion-weighted imaging (DWI).
METHODS: Eighteen individuals on combination antiretroviral therapy (cART), with mean age of 56 years, underwent medical history review, neuroimaging, and on the day of imaging, blood draw for assay of 20 plasma cytokines and flow cytometric characterization of peripheral blood mononuclear cell subsets. Predictors of n-acetyl aspartate, choline, myoinositol, glutamate/glutamine, fractional anisotropy and mean diffusivity were identified through bivariate correlation; those significant at p < .1000 were advanced to multivariate analysis, with models created for each neuroimaging outcome.
RESULTS: Monocyte subsets and diverse cytokines accounted for 16 of 25 (64%) variables predicting 1H-MRS spectra in frontal gray and white matter and basal ganglia; monocyte subsets did not predict any DWI characteristic. In contrast, age, presence of hypertension, and duration of HIV infection accounted for 13 of 25 (52%) variables predicting diffusion characteristics in the corpus callosum, thalamic radiations, and basal ganglia but only 3 of 25 (12%) predictors of 1H-MRS features.
CONCLUSIONS: 1H-MRS neurometabolites were most often predicted by immunologic factors sensitive to temporal variation, whereas DWI metrics were more often related to longer-term disease state. In multi-morbid cART-era populations, selection and interpretation of neuroimaging modalities should account for complex temporal and pathogenetic influences of immunologic abnormality, disease state, and aging.
© 2021 American Society of Neuroimaging.

Entities:  

Keywords:  DWI; HIV; MRS

Mesh:

Substances:

Year:  2021        PMID: 34520593      PMCID: PMC8752497          DOI: 10.1111/jon.12931

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  44 in total

1.  A combined spectroscopic and functional MRI investigation of the dorsal anterior cingulate region in opiate addiction.

Authors:  M Yücel; D I Lubman; B J Harrison; A Fornito; N B Allen; R M Wellard; K Roffel; K Clarke; S J Wood; S D Forman; C Pantelis
Journal:  Mol Psychiatry       Date:  2007-01-23       Impact factor: 15.992

2.  Physiologic variability of single-voxel proton MR spectroscopic measurements at 3T.

Authors:  R Mark Wellard; Regula S Briellmann; Claire Jennings; Graeme D Jackson
Journal:  AJNR Am J Neuroradiol       Date:  2005-03       Impact factor: 3.825

3.  Effects of comorbidity burden and age on brain integrity in HIV.

Authors:  Rowan Saloner; Robert K Heaton; Laura M Campbell; Anna Chen; Donald Franklin; Ronald J Ellis; Ann C Collier; Christina Marra; David B Clifford; Benjamin Gelman; Ned Sacktor; Susan Morgello; J Allen McCutchan; Scott Letendre; Igor Grant; Christine Fennema-Notestine
Journal:  AIDS       Date:  2019-06-01       Impact factor: 4.177

4.  Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals.

Authors:  Scott L Letendre; Jialin C Zheng; Marcus Kaul; Constantin T Yiannoutsos; Ronald J Ellis; Michael J Taylor; Jennifer Marquie-Beck; Bradford Navia
Journal:  J Neurovirol       Date:  2011-01-19       Impact factor: 2.643

5.  Evaluation of early cerebral metabolic, perfusion and microstructural changes in HCV-positive patients: a pilot study.

Authors:  Joanna Bladowska; Anna Zimny; Brygida Knysz; Krzysztof Małyszczak; Anna Kołtowska; Paweł Szewczyk; Jacek Gąsiorowski; Michał Furdal; Marek J Sąsiadek
Journal:  J Hepatol       Date:  2013-05-13       Impact factor: 25.083

6.  A multi-center 1H MRS study of the AIDS dementia complex: validation and preliminary analysis.

Authors:  Patricia Lani Lee; Constantin T Yiannoutsos; Thomas Ernst; Linda Chang; Christina M Marra; Jeffrey G Jarvik; Todd L Richards; Edmund W Kwok; Dennis L Kolson; David Simpson; Cheuk Y Tang; Giovanni Schifitto; Leena M Ketonen; Dieter J Meyerhoff; Robert E Lenkinski; R Gilberto Gonzalez; Bradford A Navia
Journal:  J Magn Reson Imaging       Date:  2003-06       Impact factor: 4.813

7.  Diffusion tensor imaging and MR spectroscopy in hypertension and presumed cerebral small vessel disease.

Authors:  Arani Nitkunan; Rebecca A Charlton; Dominick J O McIntyre; Thomas R Barrick; Franklyn A Howe; Hugh S Markus
Journal:  Magn Reson Med       Date:  2008-03       Impact factor: 4.668

8.  White matter structure alterations in HIV-1-infected men with sustained suppression of viraemia on treatment.

Authors:  Tanja Su; Matthan W A Caan; Ferdinand W N M Wit; Judith Schouten; Gert J Geurtsen; James H Cole; David J Sharp; Frans M Vos; Maria Prins; Peter Portegies; Peter Reiss; Charles B Majoie
Journal:  AIDS       Date:  2016-01       Impact factor: 4.177

9.  White matter abnormalities correlating with memory and depression in heroin users under methadone maintenance treatment.

Authors:  Wei-Che Lin; Kun-Hsien Chou; Chien-Chih Chen; Chu-Chung Huang; Hsiu-Ling Chen; Cheng-Hsien Lu; Shau-Hsuan Li; Ya-Ling Wang; Yu-Fan Cheng; Ching-Po Lin
Journal:  PLoS One       Date:  2012-04-09       Impact factor: 3.240

10.  HIV DNA reservoir increases risk for cognitive disorders in cART-naïve patients.

Authors:  Victor G Valcour; Jintanat Ananworanich; Melissa Agsalda; Napapon Sailasuta; Thep Chalermchai; Alexandra Schuetz; Cecilia Shikuma; Chin-Yuan Liang; Supunee Jirajariyavej; Pasiri Sithinamsuwan; Somporn Tipsuk; David B Clifford; Robert Paul; James L K Fletcher; Mary A Marovich; Bonnie M Slike; Victor DeGruttola; Bruce Shiramizu
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.